Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Reoxygenation of mouse mammary carcinoma by Fluosol-DA 20% and carbogen

Thesis/Dissertation ·
OSTI ID:5715016
The purpose of this study was to investigate the feasibility of using Fluosol-DA 20% in combination with carbogen inhalation to improve the radiotherapy of SCK tumors in A/J mice. The effect of i.v. injected Fluosol-DA and carbogen inhalation on the response of tumors to single and fractionated irradiation, and that on the changes in hypoxic cell fraction in the tumors were studied. The radiation-induced tumor growth delay and cure was enhanced by a D.M.F. of 2.10 and 1.86, respectively. The treatment slightly increased radiation-induced skin damage by a factor of 1.17 resulting in a therapeutic gain of 1.79 for growth delay and 1.59 for curability. Tumor growth delay by fractionated irradiation was enhanced by Fluosol-DA and carbogen treatment with a D.M.F. of 1.63. The hypoxic cell fraction, as measured with an in vivo-in vitro cloning method, was 39% in control tumors, and it decreased to only 5% in the tumors of animals treated with Fluosol-DA plus carbogen breathing.
Research Organization:
Minnesota Univ., Minneapolis, MN (USA)
OSTI ID:
5715016
Country of Publication:
United States
Language:
English

Similar Records

Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside
Journal Article · Fri Apr 30 00:00:00 EDT 1993 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:6936312

Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA
Journal Article · Fri Aug 01 00:00:00 EDT 1986 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6963200

Variation in tumor response to fluosol-DA (20%)
Journal Article · Mon May 01 00:00:00 EDT 1989 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6067940